Disparities in Cancer Care

Alexander B. Olawaiye, MD, discusses how social and biological determinants can affect care outcomes across cancer subtypes and what steps community and academic oncologists can take to ensure these disparities are recognized.

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

One of the primary goals of the ECOG-ACRIN Health Equity Committee is to continue addressing disparities that limit the representation of minority populations in cancer clinical trials.

Many Americans, particularly those in communities of color or socially and economically challenged populations, are presenting with advanced-stage disease, enduring aggressive treatment, and dying from cancers that should be detected early.

Anna Woloszynska, PhD, discusses the role of community outreach in addressing disparities in prostate cancer.

Health care disparities remain a major issue in cancer care, and factors contributing to this inequality stretch far beyond access to clinical care.

The National Comprehensive Cancer Network is one of many organizations that is taking a stand against inequity in health care by aligning themselves with the new 3-year campaign, entitled “Close the Care Gap,” led by the Union for International Cancer Control.

Melissa A. Simon, MD, MPH, discusses unmet needs regarding clinical trials for underserved populations with cancer, highlights the key objectives of the ECOG-ACRIN Health Equity Committee and the US Preventive Services Task Force, and shares her advice to health care professionals in the cancer space who are working to bridge some of these disparities.

The Biden-Harris administration has announced a plan to restart the Cancer Moonshot initiative, which President Joe Biden first launched as vice president of the Obama administration in 2016.

Melissa A. Simon, MD, MPH, explains why all researchers, oncologists, and health care professionals play a role in safeguarding equity in clinical trials.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, provide advice to female oncologists who are just starting out their careers.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss how and/or if any mentors they had during their careers helped them overcome gender-related challenges they experienced.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, share insight on how the corporate culture has changed in oncology practices with regard to gender inequality.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss some of the gender-related obstacles that they experienced throughout their careers as female oncologists.

Laura Farrington, DO, Elesyia Outlaw-Evans, MD, and Ruchi Garg, MD, discuss their early experiences as female oncologists and some of the gender-related challenges they faced during their careers.

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.

Dhyan Chandra, PhD, discusses the need for resources to evaluate racial disparities in prostate cancer.

Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and their advice to young women entering the field.

Raymond U. Osarogiagbon, MD, FACP, discusses geographic disparities in lung cancer.

R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.

Anna Woloszynska, PhD, discusses continued research efforts investigating racial disparities in prostate cancer.

Dhyan Chandra, PhD, discusses evaluating biological differences between African American and Caucasian men with prostate cancer.

Melissa A. Simon, MD, discusses ensuring health equity in cancer care.

Edith P. Mitchell, MD, MACP, FCPP, FRCS, shared the inspiration behind the ECOG-ACRIN Health Equity Committee, and discusses ECOG-ACRIN’s efforts in addressing health disparities in cancer care.

Anna Woloszynska, PhD, discusses the need to assess biological factors of racial disparities in prostate cancer.